Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO)

72 filings reported holding LXEO - Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29.7M shares of 55.6M outstanding shares and own 53.52% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (3.76M shares), CITADEL ADVISORS LLC (2.72M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.6M shares), D1 Capital Partners L.P. (2.51M shares), Omega Fund Management, LLC (2.36M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.86M shares), BlackRock, Inc. (1.63M shares), Frazier Life Sciences Management, L.P. (1.25M shares), Blackstone Inc. (1.16M shares), and Novo Holdings A/S (1.12M shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.